Literature DB >> 30213795

SIRT2-mediated inactivation of p73 is required for glioblastoma tumorigenicity.

Kosuke Funato1,2, Tomoatsu Hayashi1, Kanae Echizen1, Lumi Negishi1, Naomi Shimizu1, Ryo Koyama-Nasu1, Yukiko Nasu-Nishimura1, Yasuyuki Morishita3, Viviane Tabar2, Tomoki Todo4, Yasushi Ino4, Akitake Mukasa4, Nobuhito Saito4, Tetsu Akiyama5.   

Abstract

Glioblastoma is one of the most aggressive forms of cancers and has a poor prognosis. Genomewide analyses have revealed that a set of core signaling pathways, the p53, RB, and RTK pathways, are commonly deregulated in glioblastomas. However, the molecular mechanisms underlying the tumorigenicity of glioblastoma are not fully understood. Here, we show that the lysine deacetylase SIRT2 is required for the proliferation and tumorigenicity of glioblastoma cells, including glioblastoma stem cells. Furthermore, we demonstrate that SIRT2 regulates p73 transcriptional activity by deacetylation of its C-terminal lysine residues. Our results suggest that SIRT2-mediated inactivation of p73 is critical for the proliferation and tumorigenicity of glioblastoma cells and that SIRT2 may be a promising molecular target for the therapy of glioblastoma.
© 2018 The Authors.

Entities:  

Keywords:  SIRT2; cancer stem cells; glioblastoma; p73

Mesh:

Substances:

Year:  2018        PMID: 30213795      PMCID: PMC6216266          DOI: 10.15252/embr.201745587

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  41 in total

1.  Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination.

Authors:  S Nakamura; J A Roth; T Mukhopadhyay
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2.

Authors:  Barrie Peck; Chun-Yuan Chen; Ka-Kei Ho; Paolo Di Fruscia; Stephen S Myatt; R Charles Coombes; Matthew J Fuchter; Chwan-Deng Hsiao; Eric W-F Lam
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

3.  SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity.

Authors:  Hyun-Seok Kim; Athanassios Vassilopoulos; Rui-Hong Wang; Tyler Lahusen; Zhen Xiao; Xiaoling Xu; Cuiling Li; Timothy D Veenstra; Bing Li; Hongtao Yu; Junfang Ji; Xin Wei Wang; Seong-Hoon Park; Yong I Cha; David Gius; Chu-Xia Deng
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

4.  Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis.

Authors:  Thorsten Stiewe; Carmen C Theseling; Brigitte M Pützer
Journal:  J Biol Chem       Date:  2002-02-13       Impact factor: 5.157

5.  Regulation of SIRT2-dependent α-tubulin deacetylation by cellular NAD levels.

Authors:  Renate Hvidsten Skoge; Christian Dölle; Mathias Ziegler
Journal:  DNA Repair (Amst)       Date:  2014-05-10

6.  The SIRT2 Deacetylase Stabilizes Slug to Control Malignancy of Basal-like Breast Cancer.

Authors:  Wenhui Zhou; Thomas K Ni; Ania Wronski; Benjamin Glass; Adam Skibinski; Andrew Beck; Charlotte Kuperwasser
Journal:  Cell Rep       Date:  2016-10-25       Impact factor: 9.423

7.  A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity.

Authors:  Hui Jing; Jing Hu; Bin He; Yashira L Negrón Abril; Jack Stupinski; Keren Weiser; Marisa Carbonaro; Ying-Ling Chiang; Teresa Southard; Paraskevi Giannakakou; Robert S Weiss; Hening Lin
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

Review 8.  Sorting out functions of sirtuins in cancer.

Authors:  M Roth; W Y Chen
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

Review 9.  p73: Friend or foe in tumorigenesis.

Authors:  Gerry Melino; Vincenzo De Laurenzi; Karen H Vousden
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

Review 10.  p73 Alternative Splicing: Exploring a Biological Role for the C-Terminal Isoforms.

Authors:  Polina Vikhreva; Gerry Melino; Ivano Amelio
Journal:  J Mol Biol       Date:  2018-05-04       Impact factor: 5.469

View more
  16 in total

1.  NAD metabolism in aging and cancer.

Authors:  John Wr Kincaid; Nathan A Berger
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-05

Review 2.  Updates on the epigenetic roles of sirtuins.

Authors:  Tatsiana Kosciuk; Miao Wang; Jun Young Hong; Hening Lin
Journal:  Curr Opin Chem Biol       Date:  2019-03-12       Impact factor: 8.822

3.  The sirtuin family in cancer.

Authors:  Luis Filipe Costa-Machado; Pablo J Fernandez-Marcos
Journal:  Cell Cycle       Date:  2019-07-25       Impact factor: 4.534

4.  SIRT2 promotes murine melanoma progression through natural killer cell inhibition.

Authors:  Manchao Zhang; Scarlett Acklin; John Gillenwater; Wuying Du; Mousumi Patra; Hao Yu; Bo Xu; Jianhua Yu; Fen Xia
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

Review 5.  Resveratrol's Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism.

Authors:  Aranka Brockmueller; Saba Sameri; Alena Liskova; Kevin Zhai; Elizabeth Varghese; Samson Mathews Samuel; Dietrich Büsselberg; Peter Kubatka; Mehdi Shakibaei
Journal:  Cancers (Basel)       Date:  2021-01-07       Impact factor: 6.639

6.  Sirtuin 2 in Endometrial Cancer: A Potential Regulator for Cell Proliferation, Apoptosis and RAS/ERK Pathway.

Authors:  Yanjuan Guo; Nannan Zhao; Jianli Zhou; Jianxin Dong; Xing Wang
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 7.  Deacetylation of Transcription Factors in Carcinogenesis.

Authors:  Marta Halasa; Kamila Adamczuk; Grzegorz Adamczuk; Syeda Afshan; Andrzej Stepulak; Marek Cybulski; Anna Wawruszak
Journal:  Int J Mol Sci       Date:  2021-10-30       Impact factor: 5.923

Review 8.  The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy.

Authors:  Guo Li; Yuan Tian; Wei-Guo Zhu
Journal:  Front Cell Dev Biol       Date:  2020-09-29

9.  Overexpression of sirtuin 2 and its association with prognosis in acute ischemic stroke patients.

Authors:  Yun Zhang; Qianfeng Yan; Yan Zhang
Journal:  J Clin Lab Anal       Date:  2021-02-22       Impact factor: 2.352

10.  Sirtuin 2 knockdown inhibits cell proliferation and RAS/ERK signaling, and promotes cell apoptosis and cell cycle arrest in multiple myeloma.

Authors:  Tianling Ding; Jie Hao
Journal:  Mol Med Rep       Date:  2021-09-03       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.